DREAMM

The DREAMM clinical development program

Investigating BCMA-targeted antibody-drug conjugate therapy in multiple myeloma

Clinical trials

DREAMM 2

3rd Line monotherapy study

A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Low dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma1

DREAMM 4

4th Line combination study

A Phase 1/2 Single Arm Open-Label Study to Explore Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma2

DREAMM 5

4th Line combination study

A Phase 1/2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin as Monotherapy and in Combination With Anticancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma3

DREAMM 6

2nd Line combination study

A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate Belantamab Mafodotin Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma4,5

DREAMM 7

2nd Line combination study

A Multicenter, Open-Label, Randomized Phase 3 Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma6

DREAMM 8

2nd Line combination study

A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma7

DREAMM 9

1st Line combination study

A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma8

DREAMM 12

3rd Line monotherapy study

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function9

DREAMM 13

3rd Line monotherapy study

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function10

DREAMM 14

4th Line monotherapy study

A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-agent Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma11

Mechanism of action

Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA mAb conjugated to the cytotoxic payload mafodotin12

About multiple myeloma and BCMA

Multiple myeloma is characterized by the uncontrolled growth of malignant plasma cells. BCMA, a membrane protein, is expressed on all multiple myeloma cells and supports myeloma cell proliferation and survival. Belantamab mafodotin was designed to specifically bind to BCMA and eliminate myeloma cells by a multimodal mechanism.12-14

Belantamab Mafodotin

BCMA, B-cell maturation antigen; mAb, monoclonal antibody.

DREAMM

SE-GBL-BLM-WCNT-200008 June 2022

This information is intended for healthcare providers only. This website includes ongoing clinical trials for both approved and investigational compounds. Some agents are approved in select indications. Inclusion in this website does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov. All clinical study information updated as of May 2021.

GSK

© 2001-2022 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.

GlaxoSmithKline plc. Registered in England and Wales No. 3888792.

Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.